Dr. Warlick is an Assistant Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. Her clinical and research efforts focus on the treatment of hematologic malignancies. She has particular interest in myeloid malignancies and the development of new strategies utilizing hematopoietic stem cell transplantation, traditional chemotherapeutics, as well as novel biologic modifiers to treat this diverse group of diseases.
Maria Baer joined the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, Maryland in 2007 as director of hematologic malignancies and professor of medicine and molecular medicine, University of Maryland School of Medicine. She previously served as chief of the leukemia section at Roswell Park Cancer Institute and professor of medicine and associate professor of molecular pharmacology and cancer therapeutics at the University at Buffalo School of Medicine and Biomedical Sciences in Buffalo, New York.
A 24-year-old man from Ecuador presents to your clinic with dyspnea on exertion, bruising, and petechiae. He is noted to be pancytopenic with ANC 430,
Hypoplastic BM disorders in children and adolescents comprise a broad spectrum of disorders. Acquired severe
Current immunosuppressive treatment (IST) induces remissions in 50%-70% of patients with
Background. Due to increased rates of secondary solid organ cancer in patients with severe
he role of CD4(+) T-cells in the pathogenesis of AA is not well characterized. The focus of this study is to investigate the role of CD4(+) T-cells in AA with particular emphasis on CD4(+) regulatory and effector T-cell subsets and correlation with disease severity. 63 patients(48 at diagnosis) with acquired AA were studied. Numbers of Th1 and Th2-cells were significantly higher in AA compared with age matched healthy donors (HDs) (p=0.03) (p=0.006).